{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:10:38Z","timestamp":1791497438717,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"crossref","award":["21K15392"],"award-info":[{"award-number":["21K15392"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00428-021-03256-6","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:02:56Z","timestamp":1643821376000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["TGFB1 mRNA expression is associated with poor prognosis and specific features of inflammation in ccRCC"],"prefix":"10.1007","volume":"480","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-8357","authenticated-orcid":false,"given":"Taishi","family":"Takahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Satou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneko","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"3256_CR1","unstructured":"Moch H, Humprey P, Ulbright TM, Reuter V (2016) WHO classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, France, pp 14\u201317"},{"key":"3256_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","volume":"30","author":"NK Janzen","year":"2003","unstructured":"Janzen NK, Kim HL, Figlin RA et al (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843","journal-title":"Urol Clin North Am"},{"key":"3256_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ (2017) Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376:354","journal-title":"N Engl J Med"},{"key":"3256_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124","journal-title":"Science"},{"key":"3256_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/2326-6066.CIR-16-0110","volume":"4","author":"G de Velasco","year":"2016","unstructured":"de Velasco G, Miao D, Voss MH et al (2016) Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups. Cancer Immunol Res 4:820","journal-title":"Cancer Immunol Res"},{"key":"3256_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52:17","journal-title":"Immunity"},{"key":"3256_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z et al (2020) Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 26:909","journal-title":"Nat Med"},{"key":"3256_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB et al (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24:749","journal-title":"Nat Med"},{"key":"3256_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544","journal-title":"Nature"},{"key":"3256_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.18632\/oncotarget.26682","volume":"10","author":"S Tretbar","year":"2019","unstructured":"Tretbar S, Krausbeck P, Muller A et al (2019) TGF-beta inducible epithelial-to-mesenchymal transition in renal cell carcinoma. Oncotarget 10:1507","journal-title":"Oncotarget"},{"key":"3256_CR11","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1111\/cas.14422","volume":"111","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Ogawa T, Sano R et al (2020) Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Sci 111:1943","journal-title":"Cancer Sci"},{"key":"3256_CR12","first-page":"1","volume":"34","author":"M Takatori","year":"2020","unstructured":"Takatori M, Sakihama S, Miyara M et al (2020) A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia\/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1. Mod Pathol 34:1","journal-title":"Mod Pathol"},{"key":"3256_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone marrow transplant 48:452","journal-title":"Bone marrow transplant"},{"key":"3256_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549","journal-title":"Nature"},{"key":"3256_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massague J (2019) Transforming growth factor-beta signaling in immunity and cancer. Immunity 50:924","journal-title":"Immunity"},{"key":"3256_CR16","doi-asserted-by":"publisher","first-page":"69 e11","DOI":"10.1016\/j.urolonc.2014.06.005","volume":"33","author":"S Lebdai","year":"2015","unstructured":"Lebdai S, Verhoest G, Parikh H et al (2015) Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol 33:69 e11","journal-title":"Urol Oncol"},{"key":"3256_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello D, Elez E, Tabernero J et al (2020) Clinical development of therapies targeting TGFbeta: current knowledge and future perspectives. Ann Oncol 31:1336","journal-title":"Ann Oncol"},{"key":"3256_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1078-0432.CCR-09-1758","volume":"16","author":"L Wang","year":"2010","unstructured":"Wang L, Wen W, Yuan J et al (2010) Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells. Clin Cancer Res 16:164","journal-title":"Clin Cancer Res"},{"key":"3256_CR19","doi-asserted-by":"publisher","first-page":"35917","DOI":"10.18632\/oncotarget.9177","volume":"7","author":"RT Sitaram","year":"2016","unstructured":"Sitaram RT, Mallikarjuna P, Landstrom M et al (2016) Transforming growth factor-beta promotes aggressiveness and invasion of clear cell renal cell carcinoma. Oncotarget 7:35917","journal-title":"Oncotarget"},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.humpath.2011.06.019","volume":"43","author":"AK Bostrom","year":"2012","unstructured":"Bostrom AK, Moller C, Nilsson E et al (2012) Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition. Hum Pathol 43:708","journal-title":"Hum Pathol"},{"key":"3256_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J et al (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19:307","journal-title":"Nat Rev Cancer"},{"key":"3256_CR22","first-page":"1","volume":"71","author":"T Takahara","year":"2020","unstructured":"Takahara T, Satou A, Tsuzuki T (2020) Synchronous clear cell renal cell carcinoma and clonal plasmacytoid cell infiltration: a case report and literature review. Pathol Int 71:1","journal-title":"Pathol Int"},{"key":"3256_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41416-018-0266-8","volume":"119","author":"E Sjoberg","year":"2018","unstructured":"Sjoberg E, Frodin M, Lovrot J et al (2018) A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. Br J Cancer 119:840","journal-title":"Br J Cancer"},{"key":"3256_CR24","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-12-1377","volume":"72","author":"A Cipponi","year":"2012","unstructured":"Cipponi A, Mercier M, Seremet T et al (2012) Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 72:3997","journal-title":"Cancer Res"},{"key":"3256_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.iy.08.040190.001511","volume":"8","author":"FD Finkelman","year":"1990","unstructured":"Finkelman FD, Holmes J, Katona IM et al (1990) Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8:303","journal-title":"Annu Rev Immunol"},{"key":"3256_CR26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2326-6066.CIR-18-0517","volume":"7","author":"HH Workel","year":"2019","unstructured":"Workel HH, Lubbers JM, Arnold R et al (2019) A transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res 7:784","journal-title":"Cancer Immunol Res"},{"key":"3256_CR27","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7\u2013H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101:17174","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3256_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI98047","volume":"128","author":"D Zamarin","year":"2018","unstructured":"Zamarin D, Ricca JM, Sadekova S et al (2018) PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest 128:1413","journal-title":"J Clin Invest"},{"key":"3256_CR29","doi-asserted-by":"publisher","first-page":"viii529","DOI":"10.1093\/annonc\/mdy292.085","volume":"29","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L (2018) Updated results of M7824 (MSB0011359C) a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1 in second-line (2L) NSCLC. Ann Oncol 29:viii529","journal-title":"Ann Oncol"},{"key":"3256_CR30","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20:1370","journal-title":"Lancet Oncol"},{"key":"3256_CR31","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Robbins PB, Powles T et al (2020) Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 26:1733","journal-title":"Nat Med"},{"key":"3256_CR32","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302","journal-title":"J Thorac Oncol"},{"key":"3256_CR33","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.celrep.2017.07.043","volume":"20","author":"D Lindgren","year":"2017","unstructured":"Lindgren D, Eriksson P, Krawczyk K et al (2017) Cell-type-specific gene programs of the normal human nephron define kidney cancer subtypes. Cell Rep 20:1476","journal-title":"Cell Rep"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-021-03256-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:31:39Z","timestamp":1649334699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-021-03256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1007\/s00428-021-03256-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"4 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}